Biotech News

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.FDA / regulatory

Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemia

October 13, 2025 08:00 ET | Source: SELLAS Life Sciences Group, Inc.

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of its highly selective CDK9 inhibitor, SLS009 (tambiciclib), as a monotherapy and in combination with venetoclax in T-cell prolymphocytic leukemia (T-PLL), will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17 – 21, 2025, in Berlin, Germany.

The results highlight an in vivo patient-derived xenograft (PDX) model of relapsed/refractory T-PLL that reproduced key human clinicopathological features of the disease. In this model, SLS009 demonstrated meaningful single-agent activity as well as in combination with the BCL2 inhibitor venetoclax. Both SLS009 monotherapy and the combination prolonged overall survival (7.4 weeks and 7.9 weeks, respectively) compared to venetoclax alone (4.4 weeks), a difference that was statistically significant (p<0.05), and SLS009 achieved better control of circulating T-PLL cells in the peripheral blood relative to other treatments. The combination regimen was also well tolerated in the study.

“These results are highly encouraging and provide important preclinical evidence that selective CDK9 inhibition with SLS009 may play a critical role in the treatment of T-PLL, an aggressive leukemia with very limited treatment options,” said Dr. Dragan Cicic, Senior Vice President, Chief Development Officer at SELLAS. “Notably, SLS009 alone and in combination with venetoclax prolonged survival more effectively than venetoclax monotherapy, while demonstrating favorable tolerability. This reinforces the potential of SLS009 to improve outcomes in T-PLL and broadens its therapeutic relevance across additional hematologic malignancies that require novel treatment approaches.”

“The T-PLL patient-derived xenograft model we developed is highly robust and closely mirrors the behavior and progression of the disease in humans,” said Dr. Francisco Vega, Professor and Head of the Lymphoma Section in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center (MDACC) and lead author of the study. “This breakthrough allows for more rapid and meaningful translation into the clinic, greatly accelerating drug development by enabling us to evaluate novel therapies with strong clinical potential, such as SLS009, without waiting years for early clinical trial results.”

Poster Presentation Details:

Title: CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model

Session Date and Time : Saturday, October 18, 2025, 12:00 PM – 12:45 PM CEST; poster on display from 9:00 AM – 5:00 PM CEST

Session Title: Haematological Malignancies

Location : Poster Area Hall 25

Lead Author: Francisco Vega, MD, PhD, Hematopathology Department, University of Texas MD Anderson Cancer Center, Houston, TX

Abstract # : FPN: 1284P

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com .

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

John Fraunces

Managing Director

LifeSci Advisors, LLC

[email protected]

Related news

SLSSELLAS Life Sciences Group, Inc.2026-11-04 14:00 EST

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

SLSSELLAS Life Sciences Group, Inc.2026-11-17 12:00 EST

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

REGNRegeneron Pharmaceuticals2026-11-17 12:00 EST

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

GSKGSK plc2026-11-17 18:50 EST

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

RVMDRevolution Medicines2026-11-16 18:00 EST

European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

ANABAnaptysBio, Inc.2026-10-19 18:18 EST

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

REGNRegeneron Pharmaceuticals2026-10-16 11:00 EST

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

LEGNLegend Biotech Corporation2026-10-15 12:00 EST

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

IDYAIDEAYA Biosciences2026-11-16 21:05 EST

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

SELLAS Life Sciences Group, Inc.

Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor. Galinpepimut-S Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer...

Recent company news

SLSSELLAS Life Sciences Group, Inc.2026-11-20 21:01 EST

SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SLSSELLAS Life Sciences Group, Inc.2026-11-19 02:59 EST

SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering

SLSSELLAS Life Sciences Group, Inc.2026-11-18 12:19 EST

SELLAS Life Sciences ประกาศข้อมูลเชิงบวกที่เป็นจุดเปลี่ยนสำคัญจากการศึกษาวิจัยทางคลินิก REGAL ระยะที่ 3 ซึ่งแสดงให้เห็นว่าวัคซีนภูมิคุ้มกันบำบัดรักษามะเร็ง Galinpepimut-S (GPS) ช่วยให้อัตราการรอดชีวิตโดยรวมในผู้ป่วยโรคมะเร็งเม็ดเลือดขาวชนิดมัยออยด์เฉียบพลันดีขึ้นอย่างมีนัยสำคัญทางสถิติและมีความหมายทางการแพทย์

SLSSELLAS Life Sciences Group, Inc.2026-11-18 12:19 EST

SELLAS Life Sciences Mengumumkan Data Positif Kajian Pivotal Fasa 3 REGAL yang Menunjukkan bahawa Vaksin Kanser Imunoterapeutik Galinpepimut-S (GPS) Meningkatkan Kelangsungan Hidup Keseluruhan secara Signifikan dari Segi Statistik dan Bermakna dari Segi Klinikal dalam Kalangan Pesakit Leukemia Mieloid Akut

SLSSELLAS Life Sciences Group, Inc.2026-11-18 12:19 EST

SELLAS Life Sciences Mengumumkan Data Positif dari Uji Klinis Penting Fase 3 REGAL yang Menunjukkan bahwa Vaksin Imunoterapi Kanker Galinpepimut-S (GPS) Memberikan Peningkatan Kesintasan Keseluruhan yang Signifikan Secara Statistik dan Bermakna Secara Klinis pada Pasien Leukemia Mieloid Akut

Stock data

Close
14.86 USD
Market cap
1.55B USD
Exchange
NASDAQ
Sector
Life Science Tools
Location
United States